Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04582201 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS
A Phase 1 study, sponsored by MiNK Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT04582201 is a Phase 1 study that has completed, run by MiNK Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT04582201, a Phase 1 study, has completed, sponsored by MiNK Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
A Phase 1 study of agenT-797 to treat moderate to severe acute respiratory syndrome in Coronavirus disease 2019 (COVID-19) participants.
Interventions
- DRUG agenT-797
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2020-09-21 |
| Est. Completion | 2023-04-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04582201
The ClinicalTrials.gov registry entry for NCT04582201 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MiNK Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which agenT-797 is the first listed.
NCT04582201 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04582201 about?
NCT04582201 is a clinical study titled "A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDS". A Phase 1 study of agenT-797 to treat moderate to severe acute respiratory syndrome in Coronavirus disease 2019 (COVID-19) participants.
What is the current status of trial NCT04582201?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2020-09-21. Estimated completion is 2023-04-23.
What interventions are being tested in trial NCT04582201?
The interventions under investigation include: agenT-797 (DRUG).
Who is sponsoring clinical trial NCT04582201?
This trial is sponsored by MiNK Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.